Inozyme Pharma

Treatments for PPi-Adenosine Pathway, ENPP1 Deficiency, ABCC6 Deficiency, & calciphylaxis.

Based in MA

🤖

AI Overview

With $20K in lobbying spend across 3 quarterly filings, Inozyme Pharma is an active lobbying client. Their lobbying covers 1 issue area.

$20K
Total Spend
1
Years Active
1
Firms Hired
4
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2025$20K

Issues Lobbied

Lobbying Firms

Lobbyists

Government Agencies Targeted

These are the government entities that Inozyme Pharma disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATE
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy

FDA modernization H.R.1262 - Give Kids a Chance Act Trump administration impact on staffing at HHS and FDA Newborn screening Inflation Reduction Act (IRA) H.R.946 - ORPHAN Cures Act H.R. 1414 - Camero

H.R.1262/S.932 - Give Kids a Chance Act H.R.946 - ORPHAN Cures Act H.R. 1414 - Cameron's Law H.R.1532/S.822 - Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1492 - En

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.